flanders.bio is a dynamic, member driven organisation with currently more than 350 members from Belgium and abroad. We help our members to create value by organising Networking and Training Activities, supporting Internationalisation, providing Services and building Expertise. flanders.bio and its members want to be the proud advocates of a reputable global-impact ecosystem in life sciences.
News from flanders.bio and its members
argenx reports interim data from first cohort of Phase 2 proof-of-concept clinical trial of efgartigimod for the treatment of pemphigus vulgaris
argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced interim data from the first cohort of the Phase 2 proof-of-concept clinical trial of efgartigimod (ARGX-113) in pemphigus vulgaris (PV) patients.
CMAST attends the 2nd General Assembly of RESCEU; a European project focusing on the battle against RSV (June 21st-22nd, Oxford - UK)
In support of Janssen, CMAST – a leading consultancy and project management company in life sciences - is attending the 2nd RESCEU General Assembly on June 21st and 22nd in Oxford, UK. RESCEU is a European project – funded by IMI – that focuses on the fight against Human Respiratory Syncytial Virus (RSV), the most common cause of severe respiratory illness in infants and children worldwide. CMAST contributes to this project by providing project management services.
Sanofi complets its acquitision of Ablynx following the expiration of the squeeze-out procedure
Sanofi (Euronext: SAN; NYSE: SNY) and Ablynx announced today that Sanofi has now acquired all outstanding shares (including shares represented by American Depositary Shares ("ADSs")), warrants and convertible bonds (together, the "Securities") of Ablynx NV ("Ablynx") following the expiration of the Squeeze-out procedure.